Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Continued Early Intervention for Recent-onset Schizophrenia

This study has been terminated.
Sponsor:
Collaborator:
The Research Council of Norway
Information provided by:
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00184509
First received: September 15, 2005
Last updated: January 25, 2017
Last verified: January 2017
  Purpose
The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.

Condition Intervention Phase
Schizophrenia
Behavioral: integrated psychosocial treatment (behavior)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:
  • Rehospitalizations and psychotic relapse at two years

Secondary Outcome Measures:
  • Psychopathology, psychosocial changes, functioning, antipsychotic medication

Estimated Enrollment: 50
Study Start Date: February 1993
Estimated Study Completion Date: May 1998
Detailed Description:

Early intervention for schizophrenia has spawned considerable enthusiasm among clinicians without solid research evidence to suport its benefits and costs. The present study is a random-controlled study of integrated biomedical and psychosocial treatment on a population of recent-onset cases.

Comparison(s): 50 consecutive referrals with schizophrenic disorders of less than two years duration were allocated randomly to a comprehensive model of integrated treatment or standard care for two years. Main outcome measures was psychopathology, psychosocial functioning and hospital admissions.

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • first-episode schizophrenia

Exclusion Criteria:

  • acute psychosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184509

Locations
Norway
Norwegian University of Science and Technology
Trondheim, Norway, N-7000
Sponsors and Collaborators
Norwegian University of Science and Technology
The Research Council of Norway
Investigators
Study Director: K. Gunnar Gøtestam, MD Norwegian University of Science and Technology